A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Phase 3

Completed

Brief Summary: The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.

Recruitment & Eligibility

Inclusion Criteria

Willing and able to read, sign and date the informed consent and HIPAA documents
Willing and able to comply with all study procedures
Be at least 18 years of age
Patient-reported history of dry eye in both eyes
A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period
Artificial tear use within the past 30 days

Exclusion Criteria

Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
Unwilling to avoid wearing contact lenses for 7 days prior to first visit and for the duration of the study
Any blood donation or significant loss of blood within 56 days of Visit 1
Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
Use of any prohibited medications at any time during the study unless otherwise specified
Any significant illness that could interfere with study parameters
History of laser assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to first visit, and/or any other ocular surgical procedure within 12 months prior to first visit; or any scheduled ocular surgical procedure during the study period.
Known history of alcohol and/or drug abuse
Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Lifitegrast	Lifitegrast	Lifitegrast Ophthalmic Solution (5.0%)

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84	Baseline to Day 84	Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=few/rare punctate lesions; 2=discrete and countable lesions; 3=lesions too numerous to count, but not coalescent; 4=coalescent) with 0.5 point increments, and lower scores indicate improvement. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.
Change From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84	Baseline to Day 84	Eye dryness score was assessed on a visual analogue scale (a 7-item \[burning/stinging, itching, foreign body sensation, eye discomfort, eye dryness, photophobia, and pain\], participant-reported, symptom index) with scores ranging from 0 to 100 (0=no discomfort; 100=maximal discomfort) and lower scores indicate a better outcome.

Secondary Outcome Measures

Name	Time	Method

Locations (2): OPUS-2 Investigational Site
🇺🇸
Norfolk, Virginia, United States
OPUS-2 Investigational SIte
🇺🇸
Rancho Cordova, California, United States